Policy paper

Accelerated Access Review: response

A joint response to the Accelerated Access Review (AAR), setting out how government will improve patient access to breakthrough technologies and treatments.



The AAR made a series of recommendations to enable the NHS to:

  • improve patient outcomes
  • use the UK’s strong biosciences research and life sciences industrial base
  • enhance the international competitiveness of our life sciences industry

The response to this review sets out how government will work with industry and the health system to create an approvals system so that cost-effective breakthrough products can get to NHS patients as fast as possible.

Key elements of this response include:

  • an Accelerated Access Collaborative that will develop an accelerated access pathway to bring breakthrough products to market and then to patients as quickly as possible
  • £86 million government funding to support innovators and the NHS in overcoming barriers to getting new, innovative technologies to patients quickly
  • improved NHS England commercial capacity and capability to deliver deals that achieve better value for the NHS and innovators
Published 3 November 2017
Last updated 5 December 2017 + show all updates
  1. Replaced response document with accessible version.
  2. Accelerated Access Collaborative impact assessment added.
  3. First published.